title: Traditional weight-based vancomycin dosing is inadequate in critically ill trauma patients.
abstract: OBJECTIVE
  Our aim was to evaluate our institution's compliance with weight-based vancomycin dosing recommendations for pneumonia in critically ill injured patients and to assess the success rate in achieving therapeutic serum vancomycin levels. Additionally, we sought to assess the incidence of vancomycin-induced nephrotoxicity.
  
  
  METHODS
  All injured intensive care unit (ICU) patients receiving intravenous vancomycin between May 1, 2004 and July 31, 2010 were identified through our trauma database and pharmacy records. The initial weight-based dose was calculated and compared with vancomycin trough levels.
  
  
  RESULTS
  Thirty patients were identified who satisfied the inclusion/exclusion criteria. Only 12 patients (40%) received adequate weight-based dosing (weight-based, 30 mg/kg/day). Weight-based patients weighed significantly less than non-weight-based patients (62.7 vs. 84.2 kg, p = 0.0008). Weight-based patients were more likely to achieve therapeutic trough levels than non-weight-based patients (58 vs. 33%, p = 0.176). Of patients who achieved therapeutic trough levels, more weight-based patients achieved it at first trough than non-weight-based patients (33 vs. 5.6%, p = 0.046).
  
  
  CONCLUSIONS
  When prescribing commonly used dosing regimens, appropriate weight-based administration of vancomycin occurred in only approximately one-third of patients. Those patients who did receive weight-based vancomycin dosing were more likely to achieve therapeutic levels, both initially (33 vs. 5.6%) and overall (58 vs. 33%).
authors.affiliation: Division of Trauma, Department of Surgery, Emergency General Surgery, and Surgical Critical Care, Harvard Medical School, Massachusetts General Hospital, 165 Cambridge St. #810, Boston, 02114, MA, USA. daniel.dante.yeh@gmail.com.
authors.forename: D D
authors.initials: DD
authors.lastname: Yeh
authors.affiliation: Department of Surgery, University of California San Francisco, 513 Parnassus Avenue, Room S-321, San Francisco, 94143, CA, USA. Matthew.kutcher@ucsfmedctr.org.
authors.forename: M E
authors.initials: ME
authors.lastname: Kutcher
authors.affiliation: Department of Clinical Pharmacy, San Francisco General Hospital, University of California San Francisco, 1001 Potrero Ave., Box 1P2, San Francisco, 94143, CA, USA. kristin.lunghi@sfdph.org.
authors.forename: K
authors.initials: K
authors.lastname: Lunghi
keywords: Antibiotics; ICU; Pneumonia; Trauma; Vancomycin
references.citation: Crit Care Med. 2005 Sep;33(9):2127-8
references.pmid: 16148496
references.citation: Eur J Clin Microbiol Infect Dis. 1997 May;16(5):385-8
references.pmid: 9228481
references.citation: Clin Pharmacokinet. 2008;47(3):147-52
references.pmid: 18307369
references.citation: J Clin Pharm Ther. 2004 Aug;29(4):351-7
references.pmid: 15271102
references.citation: Antimicrob Agents Chemother. 2001 Sep;45(9):2460-7
references.pmid: 11502515
references.citation: Anesthesiology. 2009 Aug;111(2):356-65
references.pmid: 19602966
references.citation: Burns. 1992 Oct;18(5):355-61
references.pmid: 1445623
references.citation: Intensive Care Med. 2001 Feb;27(2):355-62
references.pmid: 11396279
references.citation: Chemotherapy. 1998 Jan-Feb;44(1):63-8
references.pmid: 9444411
references.citation: Lancet Infect Dis. 2001 Oct;1(3):147-55
references.pmid: 11871491
references.citation: Antimicrob Agents Chemother. 2003 Jun;47(6):2015-7
references.pmid: 12760889
references.citation: Pharmacotherapy. 1999 Mar;19(3):257-66
references.pmid: 10221365
references.citation: Int J Antimicrob Agents. 2009 Dec;34(6):555-60
references.pmid: 19782538
references.citation: J Antimicrob Chemother. 1996 Nov;38(5):865-9
references.pmid: 8961057
references.citation: Crit Care Clin. 2008 Apr;24(2):393-420, x-xi
references.pmid: 18361953
references.citation: Crit Care Med. 2005 Sep;33(9):1983-7
references.pmid: 16148469
references.citation: J Antimicrob Chemother. 2001 Feb;47(2):246
references.pmid: 11157921
references.citation: Curr Opin Infect Dis. 2009 Dec;22(6):525-34
references.pmid: 19738465
references.citation: Am J Health Syst Pharm. 2006 Dec 1;63(23):2365-70
references.pmid: 17106010
references.citation: Chest. 2002 Jul;122(1):262-8
references.pmid: 12114368
references.citation: Burns. 2010 Jun;36(4):469-76
references.pmid: 19875238
references.citation: J Trauma. 2009 Oct;67(4):802-4
references.pmid: 19820588
references.citation: Antimicrob Agents Chemother. 1993 Feb;37(2):281-6
references.pmid: 8452359
references.citation: Clin Microbiol Infect. 2006 Jan;12(1):92-5
references.pmid: 16460555
references.citation: Am J Health Syst Pharm. 2009 Jan 1;66(1):82-98
references.pmid: 19106348
references.citation: Clin Infect Dis. 1994 Apr;18(4):533-43
references.pmid: 8038306
references.citation: Clin Infect Dis. 2006 Jan 1;42 Suppl 1:S51-7
references.pmid: 16323121
references.citation: Lancet Infect Dis. 2005 Sep;5(9):581-9
references.pmid: 16122681